Mitchell Sabloff profile picture

Contact Information

Mitchell Sabloff, MSc, MDCM, FRCPC
613-737-8899 x79670

ORCID logo

Mitchell Sabloff

Clinician Investigator, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Director of the Ottawa Hospital Leukemia Program, Division of Hematology
The Ottawa Hospital
Co-Director of the Ottawa Hospital Hematology Bio-Bank, Division of Hematology
Ottawa Hospital Research Institute
Member of the Blood and Marrow Transplant Program, Division of Hematology
The Ottawa Hospital
Associate Professor, Department of Medicine
University of Ottawa

Research Interests

His research interests include refractory acute leukemia. He collaborates with a number of cooperative groups both in Canada and in North America. Locally he has helped identify a biomarker identifying patients who will be refractory to induction therapy and a drug that can improve the outcome of these patients. he is currently working on starting a trial using this biomarker and drug to better treat patients with refractory AML. he is currently the PI of the SIERRA trial for older patients w2ith refractory leukemia and has enrolled our first pt.

Brief Biography

Dr. Sabloff is the Director of the Leukemia Program, co-director of the Ottawa hospital hematology Biobank and is a member of the Blood and Marrow Transplant Program at the Ottawa Hospital. He has been working with Cancer Care Ontario on improving the care of patients with acute leukemia, across the province. Locally he has been collaborating with the Stanford lab at the Ottawa hospital research institute to identify patients who are have refractory AML and initiate clinical trials with novel therapies to improve their outcomes.

Selected Publications

1. Maganti, H. et al. Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies. Leuk. Res. 97, (2020).
2. Wan, B. A. et al. Revised 15-item MDS-specific frailty scale maintains prognostic potential. Leukemia (2020) doi:10.1038/s41375-020-01026-y.
3. Nazha, A. et al. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biol. Blood Marrow Transplant. (2020) doi:10.1016/j.bbmt.2020.08.003.
4. Fulcher, J., Leung, E., Christou, G., Bredeson, C. & Sabloff, M. Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia. Leukemia and Lymphoma vol. 61 2271–2273 (2020).
5. Altouri, S. et al. Total body irradiation (18 Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia. Bone Marrow Transplantation vol. 55 1454–1456 (2020).
6. Starkman, R. et al. An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. Leukemia 34, 1394–1406 (2020).
7. Pi, L. et al. Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature. Leuk. Res. 86, 106222 (2019).

Diseases, conditions and populations of interest

Research and clinical approaches